UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of report: June 20, 2024
Commission File Number: 001-38974
BIOPHYTIS S.A.
(Translation of registrant’s name into
English)
Stanislas Veillet
Biophytis S.A.
Sorbonne University—BC 9, Bâtiment
A 4ème étage
4 place Jussieu
75005 Paris, France
+33 1 44 27 23 00
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
x Form 20-F ¨
Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On June 20, 2024, Biophytis S.A. issued a press release announcing
that Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up €108 Million. A copy of the press
release is attached as Exhibit 99.1 to this Form 6-K.
EXHIBIT LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
BIOPHYTIS S.A. |
| |
|
|
| Date: June 20, 2024 |
By: |
/s/ Stanislas Veillet |
| |
|
Name: Stanislas Veillet |
| |
|
Title: Chairman and Chief Executive Officer |
Exhibit
99.1
Press
release
Biophytis
grants Blanver exclusive rights to BIO101
in Latin America in deal valued at up to €108 Million
| · | Biophytis
to receive upfront and milestones payments for a total amount up to €108 million, as
well as double-digit royalties on future sales of the product |
| · | Agreement
covers commercialization of BIO101 in Latin America |
| · | Biophytis
and Blanver intend to collaborate on manufacturing and joint clinical development for Latin
America |
Paris (France)
and Cambridge (Massachusetts, USA), June, 20th, 2024 – 07:00 am CET – Biophytis SA (Euronext Growth Paris
: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of
therapeutics for age-related diseases, today announces the signature of an exclusive license agreement with Blanver, one of the leading
and most trusted pharmaceutical company in Brazil, for BIO101 (20-Hydroxyecdysone) in Latin American including, but not limited to Brazil,
Mexico, Argentina and Colombia.
The agreement provides
that Blanver will be responsible for the registration, marketing and commercialization of BIO 101 (20-Hydroxyecdysone) in its various
indications: obesity, respiratory infections due to Covid-19, sarcopenia and Duchenne Muscular Dystrophy (DMD) - once Biophytis has successfully
completed the planned clinical development programmes for its drug candidate. With 40 years of history, Blanver has become an expert
in infectious diseases, osteoporosis and metabolic disorders, which is a perfect match with Biophytis. In addition of Brazil, Blanver
has an extensive network of unique distributors that covers the whole Latin America region.
Under the terms
of this partnership, Biophytis will be able to receive up to €108 million including an upfront payment and further additional payments
if certain objectives are achieved. Biophytis is also eligible to receive double-digit royalties on net sales of BIO101 (20-Hydroxyecdysone)
generated in the collaboration territory, after obtaining future marketing authorisations.
This collaboration
in one of the main pharma regions in the world, underscores the potential of BIO101 (20-Hydroxyecdysone) which is based on the positive
clinical results already obtained in several indications.
Stanislas Veillet,
CEO of Biophytis, stated: "I warmly welcome this new partnership which is a key milestone that will enable Biophytis to further
deploy its strategic roadmap, especially in obesity. This is a unique opportunity for both companies and comes at a crucial time as Brazil
is the most fast-growing pharmaceutical market, representing more than $23 billion in 2023. In the LATAM region, 100 million of patients
are suffering from obesity. We look forward to continuing our clinical and regulatory development work with Blanver over the coming months
and to exploring with them early market access opportunities for our most advanced indications. Together, we aim to deliver solutions
to patients and physicians over the years ahead."
Sergio Frangioni,
CEO of Blanver, commented: “Innovation is part of the Blanver DNA, and we are thrilled to partner with Biophytis, to bring this
unique medicine in Latin America. We are very confident that the clinical study of the novel BIO101 (20-hydroxyecdysone), will show encouraging
results, which will support the medical community to obesity, their effects and bring health and quality of life to so many patients
who suffer from this condition.”
* * * *
Press release
About BIOPHYTIS
Biophytis SA is
a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone),
our lead drug candidate, is a small molecule in development for muscular (sarcopenia, phase 3 ready and Duchenne muscular dystrophy),
respiratory (Covid-19 phase 2-3 completed) and metabolic diseases (obesity, phase 2 to be started). The company is based in Paris, France,
and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825). For more
information, visit www.biophytis.com
About BLANVER
Blanver Farmoquímica
e Farmacêutica S.A. is a Brazilian company, founded in 1984, focused on R&D, manufacture and sale of innovative medicines and
active pharmaceutical ingredients (APIs). The company plays in the segments of HIV, Hepatitis, Oncology, Hematology and Rare Disease,
providing high quality products for expanding the population's access to medicines through partnerships with the Ministry of Health and
official laboratories. Blanver is committed in always looking for innovations that will improve people's health and quality of life.
Forward-looking
statements
This press release
contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases,
you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects,"
"potential," "continues," "may," "will," "should," "could," "seeks,"
"predicts," "intends," "trends," "plans," "estimates," "anticipates" or the
negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers
to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified,
which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject
to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors
that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk
and uncertainties the Company is to face» section from the Company’s 2023 Financial Report available on BIOPHYTIS website
(www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities
and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result
of new information, future developments or otherwise, except as required by law.
Biophytis contacts
Investor relations
Nicolas Fellmann,
CFO
Investors@biophytis.com
Press
release
Pharma partners
Edouard Bieth, CBO
edouard.bieth@biophytis.com
Media
Antoine Denry: antoine.denry@taddeo.fr –
+33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr
– +33 6 38 31 90 50
Blanver contacts
Investor relations
Sergio José
Frangioni, CEO
Media
Herbert
Silva: Herbert.silva@blanver.com.br
Lilia
Lima de Almeida: lilia.almeida@blanver.com.br
Biophytis (PK) (USOTC:BPTSY)
Historical Stock Chart
From Nov 2024 to Dec 2024
Biophytis (PK) (USOTC:BPTSY)
Historical Stock Chart
From Dec 2023 to Dec 2024
